Holen Sie sich die Stockscreener-App
2.86
4.38%
0.12
Vorhandelsmarkt:
2.87
0.01
+0.35%
Schlusskurs vom Vortag:
$2.74
Offen:
$2.79
24-Stunden-Volumen:
279.55K
Relative Volume:
0.49
Marktkapitalisierung:
$181.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.08M
KGV:
-3.9178
EPS:
-0.73
Netto-Cashflow:
$-33.68M
1W Leistung:
+2.14%
1M Leistung:
+18.18%
6M Leistung:
+136.36%
1J Leistung:
+15.32%
1-Tages-Spanne:
$2.54
$2.90
1-Wochen-Bereich:
$2.54
$3.18
52-Wochen-Spanne:
$0.726
$3.9035
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Vergleichen Sie GALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.86 | 177.22M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
What drives Galectin Therapeutics Inc. stock priceDynamic investment growth - jammulinksnews.com
What analysts say about Galectin Therapeutics Inc. stockAccelerated wealth building - jammulinksnews.com
Is Galectin Therapeutics Inc. a good long term investmentAccelerated wealth building - jammulinksnews.com
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - Autocar Professional
Director’s Bold Move: Major Stock Purchase at Galectin Therapeutics! - TipRanks
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com Australia
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 By Investing.com - Investing.com Nigeria
What makes Galectin Therapeutics Inc. stock price move sharplyMarket Ready Callouts - Newser
Why Galectin Therapeutics Inc. stock attracts strong analyst attentionLow Volatility High Yield Stocks - Newser
Why Did Galectin Therapeutics (GALT) Soar 14.04%? - AInvest
How Galectin Therapeutics Inc. stock performs during market volatilityFree Discussion Group - Newser
Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics announces new $10 million credit line from Richard Uihlein - MSN
Galectin Therapeutics Secures $10M Credit Line for Growth - The Globe and Mail
Galectin Therapeutics secures $10 million credit line from board chairman By Investing.com - Investing.com South Africa
Galectin Therapeutics secures $10 million credit line from board chairman - Investing.com Australia
Galectin Therapeutics Inc. announced that it expects to receive $10 million in funding - MarketScreener
Galectin Therapeutics Secures Additional $10 million Credit Line - MarketScreener
ALVO 6-K: Alvotech discloses Ivers-Lee Group acquisition | GALT SEC FilingForm 8-K - Stock Titan
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - TradingView
Board Chairman Injects $10M Into Galectin's MASH Treatment Program: Extended Funding Through 2026 - Stock Titan
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average – Here’s What Happened - Defense World
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
What is HC Wainwright's Estimate for GALT Q2 Earnings? - MarketBeat
Equities Analysts Issue Forecasts for GALT Q2 Earnings - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World
Galectin Therapeutics Soars 22% Amid Technical Puzzles and Retail Surge - AInvest
Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria
Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus
HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus
Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belap - GuruFocus
Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment - Nasdaq
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):